The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Lymphoproliferative Disorders

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lymphoproliferative Disorders


Psychiatry related information on Lymphoproliferative Disorders


High impact information on Lymphoproliferative Disorders


Chemical compound and disease context of Lymphoproliferative Disorders


Biological context of Lymphoproliferative Disorders


Anatomical context of Lymphoproliferative Disorders


Gene context of Lymphoproliferative Disorders


Analytical, diagnostic and therapeutic context of Lymphoproliferative Disorders


  1. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. Pasquier, B., Yin, L., Fondanèche, M.C., Relouzat, F., Bloch-Queyrat, C., Lambert, N., Fischer, A., de Saint-Basile, G., Latour, S. J. Exp. Med. (2005) [Pubmed]
  2. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. Screpanti, I., Musiani, P., Bellavia, D., Cappelletti, M., Aiello, F.B., Maroder, M., Frati, L., Modesti, A., Gulino, A., Poli, V. J. Exp. Med. (1996) [Pubmed]
  3. Lethal host-versus-graft disease and hypereosinophilia in the absence of MHC I-T-cell interactions. Coudert, J.D., Foucras, G., Demur, C., Coureau, C., Mazerolles, C., Delsol, G., Druet, P., Guéry, J.C. J. Clin. Invest. (2000) [Pubmed]
  4. Prednisone in treatment of allergen-associated angio-immunoblastic lymphadenopathy. Newcom, S.R., Kadin, M.E. Lancet (1979) [Pubmed]
  5. Overexpression of src family gene for tyrosine-kinase p59fyn in CD4-CD8- T cells of mice with a lymphoproliferative disorder. Katagiri, T., Urakawa, K., Yamanashi, Y., Semba, K., Takahashi, T., Toyoshima, K., Yamamoto, T., Kano, K. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  6. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Ershler, W.B., Keller, E.T. Annu. Rev. Med. (2000) [Pubmed]
  7. X-linked lymphoproliferative disease: a progressive immunodeficiency. Morra, M., Howie, D., Grande, M.S., Sayos, J., Wang, N., Wu, C., Engel, P., Terhorst, C. Annu. Rev. Immunol. (2001) [Pubmed]
  8. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Brunkow, M.E., Jeffery, E.W., Hjerrild, K.A., Paeper, B., Clark, L.B., Yasayko, S.A., Wilkinson, J.E., Galas, D., Ziegler, S.F., Ramsdell, F. Nat. Genet. (2001) [Pubmed]
  9. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. Drappa, J., Vaishnaw, A.K., Sullivan, K.E., Chu, J.L., Elkon, K.B. N. Engl. J. Med. (1996) [Pubmed]
  10. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., Thompson, C.B., Griesser, H., Mak, T.W. Science (1995) [Pubmed]
  11. Autoimmunity and increased c-myb transcription. Mountz, J.D., Steinberg, A.D., Klinman, D.M., Smith, H.R., Mushinski, J.F. Science (1984) [Pubmed]
  12. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. Körner, H., Cretney, E., Wilhelm, P., Kelly, J.M., Röllinghoff, M., Sedgwick, J.D., Smyth, M.J. J. Exp. Med. (2000) [Pubmed]
  13. Neoplastic disorders after pediatric heart transplantation. Bernstein, D., Baum, D., Berry, G., Dahl, G., Weiss, L., Starnes, V.A., Gamberg, P., Stinson, E.B. Circulation (1993) [Pubmed]
  14. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Tallman, M.S., Hakimian, D. Blood (1995) [Pubmed]
  15. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. O'Brien, S., Kurzrock, R., Duvic, M., Kantarjian, H., Stass, S., Robertson, L.E., Estey, E., Pierce, S., Keating, M.J. Blood (1994) [Pubmed]
  16. Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders. Cabanillas, F., Legha, S.S., Bodey, G.P., Freireich, E.J. Blood (1981) [Pubmed]
  17. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. Baiocchi, R.A., Ward, J.S., Carrodeguas, L., Eisenbeis, C.F., Peng, R., Roychowdhury, S., Vourganti, S., Sekula, T., O'Brien, M., Moeschberger, M., Caligiuri, M.A. J. Clin. Invest. (2001) [Pubmed]
  18. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Wagner, S.D., Martinelli, V., Luzzatto, L. Blood (1994) [Pubmed]
  19. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Wood, G.S., Hardman, D.L., Boni, R., Dummer, R., Kim, Y.H., Smoller, B.R., Takeshita, M., Kikuchi, M., Burg, G. Blood (1996) [Pubmed]
  20. Regulation and function of cyclin D2 in B lymphocyte subsets. Chiles, T.C. J. Immunol. (2004) [Pubmed]
  21. The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders. Taylor, J.M., Kay, P.H., Spagnolo, D.V. Leukemia (2001) [Pubmed]
  22. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. Hawley, R.G., Fong, A.Z., Burns, B.F., Hawley, T.S. J. Exp. Med. (1992) [Pubmed]
  23. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Chambers, C.A., Kuhns, M.S., Allison, J.P. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  24. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors. Foa, R., Fierro, M.T., Raspadori, D., Bonferroni, M., Cardona, S., Guarini, A., Tos, A.G., di Celle, P.F., Cesano, A., Matera, L. Blood (1990) [Pubmed]
  25. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. Tangye, S.G., Phillips, J.H., Lanier, L.L., Nichols, K.E. J. Immunol. (2000) [Pubmed]
  26. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Morgan, S.J., Seymour, J.F., Grigg, A., Matthews, J.P., Prince, H.M., Wolf, M.M., Januszewicz, E.H. Leukemia (2004) [Pubmed]
  27. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. Watanabe, D., Suda, T., Hashimoto, H., Nagata, S. EMBO J. (1995) [Pubmed]
  28. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Bettelli, E., Dastrange, M., Oukka, M. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  29. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Camacho, F.I., Algara, P., Rodríguez, A., Ruíz-Ballesteros, E., Mollejo, M., Martínez, N., Martínez-Climent, J.A., González, M., Mateo, M., Caleo, A., Sánchez-Beato, M., Menárguez, J., García-Conde, J., Solé, F., Campo, E., Piris, M.A. Blood (2003) [Pubmed]
  30. Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia. Moody, J.L., Xu, L., Helgason, C.D., Jirik, F.R. Blood (2004) [Pubmed]
  31. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Trentin, L., Zambello, R., Sancetta, R., Facco, M., Cerutti, A., Perin, A., Siviero, M., Basso, U., Bortolin, M., Adami, F., Agostini, C., Semenzato, G. Cancer Res. (1997) [Pubmed]
  32. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Buggins, A.G., Mufti, G.J., Salisbury, J., Codd, J., Westwood, N., Arno, M., Fishlock, K., Pagliuca, A., Devereux, S. Blood (2002) [Pubmed]
  33. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Oksenhendler, E., Carcelain, G., Aoki, Y., Boulanger, E., Maillard, A., Clauvel, J.P., Agbalika, F. Blood (2000) [Pubmed]
  34. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Bachman, T.R., Sawitzke, A.D., Perkins, S.L., Ward, J.H., Cannon, G.W. Arthritis Rheum. (1996) [Pubmed]
  35. Oligoclonal T cell expansions in pulmonary lymphoproliferative disorders: demonstration of the frequent occurrence of oligoclonal T cells in human immunodeficiency virus-related lymphoid interstitial pneumonia. Kurosu, K., Yumoto, N., Rom, W.N., Takiguchi, Y., Jaishree, J., Nakata, K., Tatsumi, K., Mikata, A., Kuriyama, T., Weiden, M.D. Am. J. Respir. Crit. Care Med. (2002) [Pubmed]
  36. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Birkeland, S.A., Andersen, H.K., Hamilton-Dutoit, S.J. Transplantation (1999) [Pubmed]
WikiGenes - Universities